RRoche Read More Roche’s Wilserdly Joins Oral SERD Market, But Adjuvant Indication Still Pending2026-11-17 Roche’s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining…